AUTHOR=Shen Kai , Liu Bo , Zhou Xiang , Ji Yiyi , Chen Lei , Wang Qi , Xue Wei 

TITLE=The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.683793

DOI=10.3389/fonc.2021.683793

ISSN=2234-943X

ABSTRACT=<p>Positron emission tomography/computed tomography (PET/CT) is widely used in prostate cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions early. <sup>18</sup>F-FDG is the most used tracer for oncologic imaging, but it has limitations in detecting early-stage prostate cancer. <sup>68</sup>Ga-PSMA is a new tracer that has high specificity and sensibility in detecting local and metastatic tumors. But with the progression of prostate cancer, the enhancement of glucose metabolism in progressive prostate cancer provides a chance for <sup>18</sup>F-FDG. This review focuses on PET/CT in the detection and prognosis of prostate cancer, summarizing the literature on <sup>18</sup>F-FDG and <sup>68</sup>Ga-PSMA in prostate cancer and highlighting that <sup>18</sup>F-FDG has advantages in detecting local recurrence, visceral and lymph node metastases compared to <sup>68</sup>Ga-PSMA in partial progressive prostate cancer and castration-resistant prostate cancer patients. We emphasize <sup>18</sup>F-FDG PET/CT can compensate for the weakness of <sup>68</sup>Ga-PSMA PET/CT in progressive prostate cancer.</p>